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Prospects for Skin Cancer Treatment 
and Prevention: The Potential 
Contribution of an Engineered Virus
Jennifer A. Cafardi1, Rubina Shafi1,2, Mohammad Athar1–3 and  
Craig A. Elmets1–4
nonmelanoma skin cancers are among the most common human malignancies. 
Although typically not lethal, they are responsible for tissue deformity and 
substantial morbidity, particularly in high-risk populations. Solar UVB radiation—
a major etiologic factor for this kind of malignancy—produces DnA lesions such 
as cyclobutane pyrimidine dimers and 6-4 photoproducts in skin. These lesions 
are removed through nucleotide excision repair because humans lack a DnA 
glycosylase required to initiate base excision repair of pyrimidine–pyrimidine 
photoproducts but produce all the other proteins required for this process. In this 
issue, Johnson et al. show that a DnA glycosylase derived from Chlorella virus and 
engineered to enhance tissue penetration and nuclear localization can remove 
UVB-induced DnA lesions in a human skin equivalent model and that the protein 
can be incorporated into a topical formulation for the prevention and treatment 
of UVB-induced DnA damage. These results suggest that such an enzyme may be 
incorporated into regimens for the chemoprevention of skin cancers.
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When UVR interacts with skin, it 
produces photochemical changes in 
DNA that can adversely affect the skin’s 
bio logical activities and produce disease. 
Two lesions most commonly result from 
UVR exposure: cyclobutane pyrimidine 
dimers (CPDs), in which adjacent 
pyrimidine rings are coupled through 
carbon–carbon double bonds at the 5 
and 6 positions, and 6,4-pyrimidine 
pyrimidone photoproducts, in which 
adjacent pyrimidines are connected 
through a single bond between the 6 
position of one molecule and the 4 
position of the other. These alterations, 
if not restored to their original state, 
produce mutations that can ultimately 
lead to non melanoma skin cancers 
(NMSCs), including both squamous 
cell (SCCs) and basal cell carcinomas 
(BCCs) (Cleaver and Crowley, 2002). 
Fortunately, virtually all living organisms 
possess intricate repair mechanisms 
to mend damaged DNA. Bulky lesions 
such as CPDs are normally repaired by 
nucleotide excision repair, but they can 
also be restored by base excision repair 
(BER). Humans, however, can repair 
CPDs only through nucleotide exci-
sion repair (NER). Although human cells 
have most of the enzymes necessary to 
complete BER, they lack an important 
DNA glycosylase required to initiate 
the process (Cafardi and Elmets, 2008). 
The importance of DNA repair for pro-
tection from UV-induced skin cancers 
is evident if one examines individuals 
who suffer from xeroderma pigmento-
sum (XP), an inherited disease in which 
the NER pathway of DNA is deficient. 
These patients have a propensity to 
develop extensive photodamage, cuta-
neous SCCs, BCCs, and melanomas at 
an unusually early age.
Even in healthy individuals NMSCs 
are particularly common. In the United 
States alone, the estimated 1.5–3.5 mil-
lion new NMSC diagnoses each year 
exceed those of all other types of cancer 
combined. Although rarely lethal, these 
lesions are locally destructive and the 
cost of their removal represents an eco-
nomic burden to the healthcare system. 
The direct cost for treatment of NMSCs 
in the United States was estimated to be 
$1.5 billion in 2004, and if actinic ker-
atoses—premalignant lesions that may 
progress to SCCs—were included, the 
direct cost would increase to over $2.3 
billion (Bickers et al., 2006). In contrast 
to most other malignancies, in which 
the incidence has stabilized or declined, 
the rate of NMSCs continues to rise 
(Athas et al., 2003; Karagas et al., 1999). 
Moreover, in a population-based retro-
spective study from 1976 to 2003, the 
incidence of BCCs and SCCs in patients 
under 40 years old was found to be 
increasing significantly (Christenson et 
al., 2005).
Efforts to prevent actinic keratoses and 
NMSCs have been directed at counseling 
patients to limit the amount of UVR that 
reaches the skin, either through avoid-
ance of sun exposure and tanning bed use 
or through the application of sunscreens. 
The American Academy of Dermatology, 
the American Cancer Society, and other 
organizations throughout the world have 
developed sophisticated educational 
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materials to inform the public of the 
deleterious effects of excessive UVR 
exposure and how to prevent them. 
Unfortunately, these campaigns have met 
with varying degrees of success.
Chemoprevention, the prevention of 
cancer through dietary manipulation or 
pharmacological intervention, repre-
sents an alternative to sun avoidance and 
the application of sunscreens for inhibit-
ing skin cancer. Because chemopreven-
tive agents are administered chronically 
to healthy individuals, emphasis must be 
placed not only on efficacy but also on 
the absence of serious side effects. The 
ideal chemopreventive agent would be 
characterized by (i) little or no toxicity, 
(ii) high efficacy, (iii) easy administra-
tion, (iv) a known mechanism of action, 
and (v) acceptance of its use by indi-
viduals at risk for cancer. Preclinical and 
clinical evaluations of chemoprevention 
drugs differ substantially from those of 
chemotherapeutic agents (Mukhtar and 
Agarwal, 1996).
Drugs that target DNA damage or its 
repair fulfill many of the criteria of the 
ideal chemopreventive agent, and they 
have attracted particular attention. For 
example, the bacteriophage T4 pyrimi-
dine dimer-specific DNA glycosylase 
(T4-PDG), also known as T4 endonu-
clease V (T4N5), enhances DNA repair 
and reduces the frequency of UV-induced 
mutations in epidermal keratinocytes. 
Liposome-encapsulated T4N5 applied 
to human skin in vivo can be detected in 
keratinocytes, where it initiates repair of 
UV-induced DNA damage through BER. 
In a phase II clinical trial, patients with XP 
treated with liposome-encapsulated T4N5 
for one year showed a marked reduction 
in actinic keratoses and BCCs as com-
pared with those treated with placebo 
(Yarosh et al., 2001). As mentioned pre-
viously, patients with XP have a defect 
in DNA repair, unlike most individuals 
who develop NMSCs, and the efficacy 
of T4N5 has not yet been determined in 
DNA repair-proficient individuals.
Photolyase is an enzyme derived from 
the algae Anacystis nidulans. Following 
activation by visible light, photolyase 
unlinks CPDs and 6-4 pyrimidine pyrim-
idone photoproducts, restoring them 
to their native conformation (Li et al., 
2010). Application to UVB-irradiated 
skin in vivo in a liposomal preparation 
followed by activation with photoreac-
tivating light also led to a reduction in 
CPDs (Stege et al., 2000).
In this issue, Johnson et al. report a 
novel enzyme that enhances the repair 
of UV-damaged DNA: pyrimidine dimer 
glycosylase, expressed by the Chlorella 
virus (Cv-pdg). Because the enzyme 
localizes primarily in the cytoplasm rather 
than in the nucleus and because it would 
not be expected to penetrate through the 
stratum corneum when applied topically, 
the invest igators incorporated a nuclear 
localization signaling sequence (NLS) and 
a membrane permeabilization peptide 
(TAT) into the molecule. The modi-
fied enzyme is particularly interesting 
because the engineered structure allows 
for its effective penetration through the 
top layers of the skin without the need 
for encapsulation into a delivery vehicle. 
Cv-pdg contributes to BER in prokaryotic 
species and is similar to the one lacking 
in human cells. In the study, Cv-pdg-NLS-
TAT was applied topically to human skin 
equivalents. The engineered enzyme was 
absorbed and reached the basal layer of 
the epidermal equivalent. There, it local-
ized in the nucleus and was found to be 
effective at diminishing a high percent-
age of CPDs when administered either 
before or after exposure to UVR.
These findings suggest that Cv-pdg-
NLS-TAT may have both cancer preven-
tive and therapeutic applications and 
therefore could be ideal for individuals 
at high risk for NMSCs, such as patients 
with XP, organ transplant recipients, and 
individuals with extensive photodam-
age. However, evidence of clinical effi-
cacy and tolerability for Cv-pdg-NLS-TAT 
awaits clinical trials. That Cv-pdg-NLS-
TAT did not require encapsulation into 
a delivery vehicle to reach basal kera-
tinocytes is an advantage over both 
T4N5 and photolyase. The Cv-pdg-NLS-
TAT topical enzyme also is more stable 
over a range of salt concentrations and 
temperature extremes than other topical 
formulations that accelerate the repair of 
UV-damaged DNA (McCullough, 1998). 
Furthermore, Cv-pdg-NLS-TAT showed 
favorable retention kinetics in skin cells, 
indicating that it may be ideal for devel-
oping a convenient dosing regimen for 
human application.
Although mutations in the Sonic 
hedgehog pathway (for BCCs) and in p53 
(for both BCCs and SCCs) are responsible 
for most NMSCs, some of those tumors 
lack these mutations (Athar et al., 2006). 
Because Cv-pdg-NLS-TAT is able to 
repair a broad range of DNA mutations, 
Johnson et al. (2011) postulate it could 
have broad efficacy against a variety of 
UV-induced mutations and, in contrast to 
other potential chemopreventive agents 
(Hacker et al., 2010), may be effective for 
the small number of UV-induced tumors 
without CPDs. Cv-pdg-NLS-TAT may 
also be useful in melanoma prevention 
because it has broad substrate specificity 
and an improved nuclear concentration 
caused by the NLS component.
Even if Cv-pdg-NLS-TAT is found to be 
effective, additional properties remain to 
be evaluated for it to be acceptable for 
widespread application in humans, 
including examination of its irritancy 
following chronic application and its 
cosmetic elegance.
Another important issue is the effect 
of this enzyme on the repair of oxidative 
DNA lesions induced by the reactive 
oxygen species that arise following UV 
exposure. UVB and UVA radiation can 
lead to oxidative DNA damage, such as 
8-hydroxyguanisine, which is mutagenic 
and may contribute to the development 
of skin cancers (Kunisada et al., 2005; 
Clinical Implications
•  Cv-pdg-NLS-TAT is a genetically engineered glycosylase that enables 
human skin to perform base excision repair of UVR-damaged DNA.
•  In contrast to other topically applied enzymes, Cv-pdg-NLS-TAT has 
greater nuclear localization, can penetrate into the lower levels of the 
epidermis without encapsulation into a delivery vehicle, is more stable, 
and may act against a wider variety of UVR-induced mutations.
•  Cv-pdg-NLS-TAT shows promise as a topical preventive and therapeutic 
agent for patients at high risk for UVR-induced skin cancer.
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Montaner et al., 2007). It would be 
interesting and important to determine 
whether Cv-pdg-NLS-TAT repaired 
this type of DNA damage as well. This 
enzyme may not have a direct effect on 
the repair of oxidative DNA damage, but 
it may contribute to an overall upregula-
tion of repair mechanisms in the nuclear 
environment.
Because NMSCs continue to be a 
major health and economic issue, the 
development of new treatment and pre-
ventive modalities is crucial. In addi-
tion to standard recommendations such 
as sun avoidance and the application 
of sunscreen, there are promising treat-
ments and preventive therapies on the 
horizon. Cv-pdg-NLS-TAT may be one 
such modality; future clinical studies will 
further define its efficacy and tolerability.
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Peeling Skin Syndrome:  
Genetic Defects in Late Terminal 
Differentiation of the Epidermis
Paul E. Bowden1
In this issue, Israeli and colleagues confirm that homozygous mutations in 
corneodesmosin (CDSn) cause type B peeling skin syndrome (PSS), an auto somal 
recessive skin disorder. The deletion mutation described resulted in a frame-
shift, producing a downstream premature stop codon and early truncation of the 
protein. The recently described CDSn nonsense mutation in another PSS family 
also resulted in protein truncation and nonsense-mediated mRnA decay. Type B 
generalized PSS can now be clearly distinguished from acral PSS, caused by muta-
tions in transglutaminase 5. This directly affects cornified envelope cross-linking 
rather than corneodesmosome adherence. These observations provide new 
insight into the molecular defects underlying two closely related forms of PSS.
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PSS
Peeling skin syndrome (PSS), first 
described in the early twentieth century 
(Fox, 1921), is a rare cutan eous geno-
dermatosis that is classified into two 
forms: acral PSS (APSS; OMIM 609796) 
and generalized PSS (OMIM 270300). 
Although it has been suggested (Traupe, 
1989) that the generalized form can 
be further subdivided into noninflam-
matory (type A) and inflammatory 
(type B), other phenotypes including 
those with hair and nail abnormal-
ities have also been described, further 
